Compare · LIVN vs NXL
LIVN vs NXL
Side-by-side comparison of LivaNova PLC (LIVN) and Nexalin Technology Inc. (NXL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and NXL operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.43B, about 421.8x NXL ($10.5M).
- Over the past year, LIVN is up 92.2% and NXL is down 57.0% - LIVN leads by 149.2 points.
- NXL has been more active in the news (3 items in the past 4 weeks vs 1 for LIVN).
- LIVN has more recent analyst coverage (20 ratings vs 0 for NXL).
- Company
- LivaNova PLC
- Nexalin Technology Inc.
- Price
- $80.70-1.27%
- $0.48+6.58%
- Market cap
- $4.43B
- $10.5M
- 1M return
- +1.54%
- +21.63%
- 1Y return
- +92.25%
- -56.98%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 1
- 3
- Recent ratings
- 20
- 0
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest LIVN
- LivaNova to Announce Second-Quarter 2026 Results
- Director Wilver Peter M covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 53% to 10,294 units (SEC Form 4)
- Chief Innovation Officer Tezel Ahmet converted options into 2,965 units of Ordinary Shares and covered exercise/tax liability with 1,032 units of Ordinary Shares, increasing direct ownership by 46% to 6,090 units (SEC Form 4)
- Director Bianchi Francesco covered exercise/tax liability with 486 units of Ordinary Shares, sold $96,228 worth of Ordinary Shares (1,200 units at $80.19) and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 33% to 9,584 units (SEC Form 4)
- Director Podlogar Susan M converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 170% to 5,642 units (SEC Form 4)
- Director Schermerhorn Todd C converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 39% to 12,619 units (SEC Form 4)
- SEC Form 4 filed by Director Nygaard-Andersen Jette
- Director Enxing Seng Stacy converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 30% to 15,307 units (SEC Form 4)
- Director Kozy William A converted options into 5,681 units of Ordinary Shares and covered exercise/tax liability with 682 units of Ordinary Shares, increasing direct ownership by 15% to 37,566 units (SEC Form 4)
- Director Barry James Christopher covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 82% to 7,918 units (SEC Form 4)
Latest NXL
- SEC Form DEF 14A filed by Nexalin Technology Inc.
- SEC Form PRE 14A filed by Nexalin Technology Inc.
- Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
- Nexalin Technology Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
- Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
- Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
- Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
- Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial